A3 adenosine receptor as a target for cancer therapy
P Fishman, S Bar-Yehuda, L Madi, I Cohn - Anti-cancer drugs, 2002 - journals.lww.com
Targeting the A3 adenosine receptor (A3AR) by adenosine or a synthetic agonist to this
receptor (IB-MECA and Cl-IB-MECA) results in a differential effect on tumor and on normal
cells. Both the adenosine and the agonists inhibit the growth of various tumor cell types such
as melanoma, colon or prostate carcinoma and lymphoma. This effect is specific and is
exerted on tumor cells only. Moreover, exposure of peripheral blood mononuclear cells to
adenosine or the agonists leads to the induction of granulocyte colony stimulating factor (G …
receptor (IB-MECA and Cl-IB-MECA) results in a differential effect on tumor and on normal
cells. Both the adenosine and the agonists inhibit the growth of various tumor cell types such
as melanoma, colon or prostate carcinoma and lymphoma. This effect is specific and is
exerted on tumor cells only. Moreover, exposure of peripheral blood mononuclear cells to
adenosine or the agonists leads to the induction of granulocyte colony stimulating factor (G …
